SwissMedic and Clinical Trial Applications
- a
- Aug 26, 2023
- 2 min read
When seeking to conduct a clinical trial in Switzerland, an initial Clinical Trial Application (CTA) must be submitted to Swissmedic, the Swiss Agency for Therapeutic Products. The primary objective of the CTA is to demonstrate that the proposed trial is safe, ethical, and scientifically sound.
Here are the detailed initial requirements for a CTA submission to Swissmedic:
1. Application Form:
This is the main form provided by Swissmedic specific to CTAs, and it should capture:
General information about the trial.
Details about the sponsor and contact person.
Information about the investigational medicinal product (IMP).
Details about the trial sites and investigators.
2. Clinical Trial Protocol:
This should include:
Title of the study.
Study objectives and purpose.
Detailed study design and methodology.
Definition of the study population, including inclusion and exclusion criteria.
Interventions and procedures involved.
Definition of primary and secondary endpoints.
Details on data collection and statistics.
Procedures for monitoring safety.
3. Investigator’s Brochure (IB):
This should compile all clinical and non-clinical data on the IMP known up to the time of the CTA submission, including:
Overview and description of the IMP.
Summary of pharmacological effects.
Toxicological findings from pre-clinical studies.
Results of any prior clinical studies.
Detailed safety information.
4. Patient Information & Informed Consent Forms:
This involves:
A comprehensive patient information sheet detailing the study's purpose, procedures, potential risks, and benefits.
The informed consent form that participants will be required to sign.
5. Safety Measures:
Detailed plans to monitor and manage potential risks and adverse events.
Plans for regular safety reporting to Swissmedic.
Procedures to handle unexpected serious adverse reactions.
6. Information about the IMP:
Comprehensive data on the IMP’s quality, including details on its manufacturing, control, and packaging.
Non-clinical data, including findings from pharmacological, toxicological, and pharmacokinetic studies.
Data from any prior clinical trials, if available.
7. Trial Site and Investigator Information:
A list of all sites where the trial will be conducted.
Details about the principal investigators, including their qualifications.
8. Ethics Committee Approval:
While Swissmedic and the Ethics Committees operate independently, you need to provide proof of submission to an ethics committee. If approval has already been secured, a copy of the decision should be included.
9. Insurance Coverage:
Proof that participants are insured against potential risks arising from the trial. The coverage details and the claims process should be transparent.
10. Pharmaceutical Quality:
Details about the composition, manufacturing process, quality controls, storage conditions, and stability of the IMP.
11. Fees:
Swissmedic charges fees for CTA evaluation. The exact amount and proof of payment details will be as per Swissmedic’s guidelines.
12. Additional Documents (if applicable):
Justification for placebo use, if relevant.
Special requirements or additional documentation for vulnerable populations.
Data handling, protection, and patient confidentiality details.
Important Notes:
It's advisable to regularly check Swissmedic's official guidelines as they may update requirements or procedures.
The CTA's approval is necessary before initiating a clinical trial. Upon evaluation, Swissmedic may approve, ask for revisions, or decline the application based on its merit and adherence to safety, ethical, and scientific standards.
Swissmedic maintains a defined timeline for the evaluation process, but this can vary based on the complexity of the application and other factors.
Lastly, it's often beneficial for applicants to engage in preliminary consultations with Swissmedic, especially for complex or novel trials. This can provide clarity and increase the chances of a smooth evaluation process.
Comments